Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adverum Biotechnologies, Inc. - Common Stock (NQ:ADVM)

4.170 -0.300 (-6.71%)
Streaming Delayed Price Updated: 1:45 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adverum Biotechnologies, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2021
Upgrades According to Vertical Research, the prior rating for Entergy Corp (NYSE:ETR) was changed from Hold to Buy. For the first quarter, Entergy had an EPS of $1.47,... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 5 companies set new 52-week lows. Noteables: Lufax Holding (NYSE:LU) was the largest firm on a market cap basis to set a new... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; McDonald's Profit Beats Estimates
Following the market opening Thursday, the Dow traded up 0.23% to 33,899.83 while the NASDAQ rose 0.25% to 14,086.11. The S&P also rose, gaining 0.49% to 4,203.60. The U.S.... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Galera Therapeutics (NASDAQ:GRTX) shares increased by 42.2% to $9.4 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 39.6% to $9.23 in pre-market trading after the company disclosed updated data from its randomized, multicenter, placebo-... 
Via Benzinga
Adverum's Stock Crashes After DME Gene Therapy Trial Derails On One Patient's Serious Adverse Event
Adverum Biotechnologies Inc (NASDAQ: ADVM) stock has cratered in reaction to a Suspected Unexpected Serious Adverse Reaction of hypotony (clinically-relevant decrease... 
Via Benzinga
The Sonic Fund II, L.P. Issues Presentation Correcting Adverum’s Misstatements
From The Sonic Fund II, L.P.
Via Business Wire
The Sonic Fund II, L.P. Issues Presentation Detailing Compelling Case for Immediate Board Upgrade at Adverum Biotechnologies, Inc.
From The Sonic Fund II, L.P.
Via Business Wire
The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies, Inc.
From The Sonic Fund II, L.P.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 62 stocks made new 52-week lows. Significant Points: The largest company by market cap to set a new 52-week low was Yatsen Holding (NYSE:... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows. Interesting Highlights: The largest company by market cap to set a new 52-week low was Ionis Pharmaceuticals (... 
Via Benzinga
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... 
Via Benzinga
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.